Literature DB >> 1627966

Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.

B A Fallon1, R Campeas, F R Schneier, E Hollander, J Feerick, J Hatterer, D Goetz, S Davies, M R Liebowitz.   

Abstract

In a preliminary trial, five oral-clomipramine-refractory patients with obsessive-compulsive disorder (OCD) were treated openly with 14 intravenous clomipramine infusions each. Using standardized assessments, three patients were rated as much improved, one as unchanged, and one as minimally improved. Statistically significant improvements were noted on both the Yale-Brown Obsessive Compulsive Scale and the NIMH Global OCD scores. No patient discontinued treatment because of side effects. Although the results are provocative in that three of five patients were much improved at the end of the protocol, conclusions about preferential efficacy for the intravenous route must await a placebo-controlled trial.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627966     DOI: 10.1176/jnp.4.1.70

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  3 in total

Review 1.  Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.

Authors:  L D Kochan; A I Qureshi; B A Fallon
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

2.  Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials.

Authors:  Chad T Wetterneck; Tannah E Little; Kimberly L Rinehart; Maritza E Cervantes; Emma Hyde; Monnica Williams
Journal:  J Obsessive Compuls Relat Disord       Date:  2012-01-08       Impact factor: 1.677

3.  Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Wael Karameh Karameh; Munir Khani
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-28       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.